## HSIC: Henry Schein, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 1.71 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg), momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Henry Schein, Inc. (NASDAQ:HSIC) Receives Average Recommendation of "Hold" from Analysts**
- Source: MarketBeat | 20251227T064932 | Somewhat-Bullish | Relevance: 100%
- Henry Schein, Inc. (NASDAQ:HSIC) currently holds an average "Hold" recommendation from 14 analysts, with a 12-month price target of $76.92. Despite the consensus, some analysts have issued bullish revisions, including an "outperform" rating from Evercore ISI with a $90 target and an "overweight" initiation from Barclays at $86. Institutional investors hold approximately 96.62% of the company, with significant recent purchases from firms like Ameriprise, Norges Bank, Schroder, and Bank of America.

**2. Henry Schein, Inc. $HSIC Shares Purchased by Swedbank AB**
- Source: MarketBeat | 20251225T111913 | Bullish | Relevance: 100%
- Swedbank AB increased its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 12.4% during Q3, now owning 1,299,571 shares valued at $86.25 million. This is part of a broader institutional accumulation, with hedge funds and institutions holding 96.62% of the company's stock. Henry Schein also beat earnings expectations and provided strong FY2025 guidance, though analyst sentiment remains mixed with an average "Hold" rating.

**3. Henry Schein Board Advances CEO Succession and Transition**
- Source: The Globe and Mail | 20251225T060839 | Somewhat-Bullish | Relevance: 100%
- Henry Schein's Board announced that it expects to appoint a new CEO by mid-January 2026, marking the final stage of its succession plan. Current CEO Stanley M. Bergman will remain in his roles under an extended employment agreement to ensure a smooth transition. The company, a major healthcare solutions provider, currently has a "Buy" rating and an "Outperform" assessment by TipRanksâ€™ AI Analyst.

**4. Henry Schein Extends Private Placement Facilities to 2028**
- Source: The Globe and Mail | 20251224T210836 | Somewhat-Bullish | Relevance: 100%
- Henry Schein (HSIC) announced it amended existing private placement shelf facilities with institutional investors, extending their termination dates to December 19, 2028. This move aims to secure long-term private financing, enhance balance sheet flexibility, and strengthen the company's funding position. Analysts currently rate HSIC as a Buy with an $86.00 price target, supported by strong earnings insights despite some valuation concerns.

**5. Henry Schein expects to name new CEO by mid-January 2026**
- Source: Investing.com | 20251224T180759 | Somewhat-Bullish | Relevance: 100%
- Henry Schein, Inc. announced its intention to appoint a new CEO by mid-January 2026, with the search nearing completion. Current CEO Stanley Bergman will remain until a successor is in place to ensure a smooth transition. The company, valued at $9 billion, has shown strong financial health and aggressive share buybacks, leading up to this leadership change.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $86 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($0.15M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Kohlberg Kravis Robe: 13.3% (0.0%)
- JPMORGAN CHASE & CO: 10.6% (+98.6%)
- Vanguard Group Inc: 10.2% (-7.2%)
- Artisan Partners Lim: 5.8% (+5.7%)
- Blackrock Inc.: 5.7% (-8.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.71 elevated, pricing in significant growth expectations. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 0.89 |
| 52W Range | $60.56 - $82.49 |
| Short Interest | 5.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.71 |
| Forward P/E | 14.4 |
| Current P/E | 15.5 |
| YoY Growth | 7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.8% to 0.1% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 (-1.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 54% of 20MA suggests lack of conviction. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.09% (CS: 54) | Neutral |
| RSI_14 | 58.4 | Neutral |
| MACD Histogram | -0.21 | Bearish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.097x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $76.13
- **Stop Loss:** $73.37 (3.6% risk)
- **Target:** $78.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 478
- **Position Value:** $36,390.14
- **Portfolio %:** 36.39%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-24 (Est: $1.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.28 | $1.38 | +7.9% |
| 2025Q2 | $1.19 | $1.10 | -7.6% |
| 2025Q1 | $1.11 | $1.15 | +3.6% |
| 2024Q4 | $1.21 | $1.19 | -1.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*